Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : InvestRight Club Challenge -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (2644)	9/8/1999 11:14:00 AM
From: Jeffrey L. Henken	Read Replies (2) \| Respond to of 2662

Wasatch Pharmaceutical Inc. Receives Funding For FDA Application MIDVALE, Utah--(BUSINESS WIRE)--Sept. 8, 1999--Previous announcements have indicated ongoing funding from investment banking sources providing funds for the expansion of Wasatch Pharmaceutical Inc. (OTC BB:WASP - news). As of Sept. 2, 1999, Wasatch has received funds sufficient to carry forward its plans as previously announced, including, and most importantly, its application with the FDA for seven over-the-counter products. Further, by Oct. 1, 1999, it is anticipated that an additional $1 million to $2 million will be received to apply to pursuit of other strategic goals. These include the areas of Web sites, contracts with health care providers and additional clinics and staff. Wasatch is a development-stage company engaged in research in the field of dermatology. It has developed a technology that treats acne, eczema and other common skin disorders without the undesirable side effects often associated with prescription drugs. Having successfully treated hundreds of patients in two prototype medical skin care clinics for over five years, the Company is positioned to expand its clinic operation and to introduce seven over-the-counter products subject to FDA approval. NOTE: Any statements released by Wasatch Pharmaceutical Inc. that are not strictly historical are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward-looking statements invoke risk and uncertainties that may affect the company's business prospects and performance. These include economic, competitive, governmental, technological and other factors discussed in the company's filings with the Securities and Exchange Commission. Contact: Wasatch Pharmaceutical Inc., Midvale Gary Heesch, 801/272-1709 biz.yahoo.com